Alerts

Boston Scientific have advised that subsets of ACCOLADE and VISIONIST pacemakers have an increased risk of permanently entering Safety Mode which has limited functionality.

The supply of Ozempic (semaglutide) will continue to be limited until 31 December 2025

Pharmacists can use a Serious Scarcity Substitution Instrument (SSSI) to dispense Protaphane Penfill human insulin in the place of a Protaphane InnoLet cartridge.

Caruso's Natural Health Pty Ltd is recalling certain batches of WEE LESS, BLOAT EZE and ASHWAGANDHA 7500 due to suspected tampering.

Dynamint X tablets pose a serious risk to your health and should not be taken.

Gold Max Blue capsules pose a serious risk to your health and should not be taken.

MAXMAN tablets pose a serious risk to your health and should not be taken.

Insulet is advising they have received complaints of Omnipod DASH PDM/controller battery depletion as a result of the 3G network deactivation in the region.

There is a potential for insulin leakage with the Accu-Chek Spirit 3.15 ml cartridge system due to a manufacturing problem.

Due to the concerns and difficulties caused by such shortages, we are giving patients and prescribers early notification so that they can plan ahead.

A shortage of Bicillin L-A 1.2 million unit prefilled syringes is anticipated from 20 December 2024 to 10 January 2025. A PBS-listed substitute product is available.

Pharmacists may dispense alternative brands or strengths without a new prescription.

The oral antihistamine promethazine hydrochloride, sold as Phenergan and other generic brands, should not be given to children under 6 years of age.

African Vigorous Max Strength poses a serious risk to your health and should not be taken.

We have tested a further 6 imported, unregistered ivermectin products and found they are counterfeit under the Therapeutic Goods Act 1989.

Ziyinzhuangyang tablets pose a serious risk to your health and should not be taken.

Metalyse is now available for use in all clinical settings.

Consumers and health professionals should be aware that counterfeit Ozempic-labelled pens have been imported into Australia. These pens may pose a serious health risk and should not be used. There are clear inconsistencies from the original product to look out for.

We have made a new Serious Scarcity Substitution Instrument to help manage the shortage and upcoming discontinuation of Ryzodeg 70/30 FlexTouch insulin.

The new KwikPen presentation of Mounjaro is now available but supply of all strengths of Mounjaro vials remains limited.

We have been advised that Novo Nordisk will gradually discontinue some of its earlier generation insulin products over the next 2 years.

Shortage resolved

We have become aware of an increasing number of cases of liver injury reported in scientific literature, by consumers who had taken products containing Garcinia gummi-gutta.

Pharmaceutical company Novo Nordisk has advised us that a new brand of semaglutide approved for chronic weight management, Wegovy, will be available in Australia from early August 2024.

Medicine shortage alert